Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion submitted a corrected disclosure after receiving the official 1st instance court judgment regarding the COVID-19 diagnostic kit lawsuit with Humasis, detailing the specific order and noting a separate favorable ruling of approx. KRW 3.89B in Celltrion’s counter-suit.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Decisions or Rulings on Lawsuits (Claims Exceeding Specific Amount) (Correction)
- Original Filing & Correction Date: July 3, 2025 / July 11, 2025
- Reason for Correction: Accurate reflectment of judgment details upon receipt of the official court order
- Litigation Overview:
- Case Name / Case Number: Payment for Goods / 2023Gahap100211
- Plaintiff: Humasis Co., Ltd.
- Defendant: Celltrion, Inc.
- Jurisdiction: Suwon District Court (Anyang Branch)
- Background: Dispute regarding unpaid supply contract amounts and damages related to joint COVID-19 diagnostic kit operations
- Court Order on Humasis’s Claim:
- Awarded Amount: KRW 12,710,724,105 (approx. KRW 12.71B / USD 2,094,300 + KRW 9,863,732,685)
- Ratio to Equity: 0.07% (Based on total equity of KRW 17,580,062,368,691)
- Court Order: Defendant (Celltrion) shall pay the awarded amount plus late payment interest; 90% of litigation costs borne by Plaintiff, 10% by Defendant
- Ruling on Celltrion’s Counter-Suit (Other Key Matters):
- Case Name / Plaintiff: Claim for Damages / Celltrion, Inc.
- Awarded Amount: KRW 3,887,761,421 (approx. KRW 3.89B / USD 2,587,189.29 + KRW 370,736,301)
- Court Order: Defendant (Humasis) shall pay the awarded amount plus late payment interest; 95% of costs borne by Plaintiff (Celltrion), 5% by Defendant (Humasis)
- Future Plan: Celltrion plans to appeal the 1st instance decision and actively proceed with legal measures
- Key Dates: Date of Ruling July 3, 2025 / Date of Confirmation via Receipt of Judgment July 11, 2025
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Appeal Filing and Progress in Appellate Court Proceedings
This corrected disclosure reflects the exact details of the 1st instance ruling after official receipt by Celltrion, including the decision on its counter-claim against Humasis. As Celltrion intends to file an appeal against the ruling, it is important to monitor the filing of the appeal and subsequent appellate court proceedings. Tracking the appellate process ensures verification of any potential changes to the final liability amounts. Appellate outcomes and litigation updates can be verified through future disclosures or upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
